Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson’s Disease
Journal of Parkinson’s Disease · 2024
DOI: 10.3233/jpd-240007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, 2024. Verfasst von Andrea Pilotto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Prodromal Symptoms, Biomarkers, alpha-Synuclein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The recent development of new methods to detect misfolded α-synuclein (αSyn) aggregates in biofluids and tissue biopsies in the earliest Parkinson’s disease (PD) phases is dramatically challenging the biological definition of PD. The αSyn seed amplification methods in cerebrospinal fluid (CSF) showed high sensitivity and specificity for early diagnosis of PD and Lewy bodies disorders. Several studies in isolated REM sleep behavior disorders and other at-risk populations also demonstrated a high prevalence of CSF αSyn positivity and its potential value in predicting the phenoconversion to clinically manifested diseases. Growing evidence exists for αSyn aggregates in olfactory mucosa, skin, and other tissues in subjects with PD or at-risk subjects. DOPA decarboxylase and numerous other candidates have been additionally proposed for either diagnostic or prognostic purposes in earliest PD phases. The newly described αSyn detection in blood, through its quantification in neuronally-derived exosome vesicles, represents a technical challenge that could open a new scenario for the biological diagnosis of PD. Despite this growing evidence in the field, most of method of αSyn detection and markers still need to be validated in ongoing longitudinal studies through an accurate assessment of different prodromal disease subtypes and scenarios before being definitively implemented in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
- Laboratory of Digital Neurology and Biosensors, University of Brescia, Brescia, Italy.
- Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy.
- Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy.
- Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
- Neurology Unit, Parkinson Disease and Movement Disorders Division, Department of Engineering and Medicine of Innovation, University of Verona, Verona, Italy.
Zitieren
APA
Pilotto, A., Zanusso, G., Antelmi, E., Okuzumi, A., Zatti, C., Lupini, A., Bongianni, M., Padovani, A., & Hattori, N. (2024). Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-240007
Vancouver
Pilotto A, Zanusso G, Antelmi E, Okuzumi A, Zatti C, Lupini A, et al. Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson’s Disease. Journal of Parkinson’s Disease. 2024. doi:10.3233/jpd-240007
BibTeX
@article{Pilotto2024,
author = {Pilotto, Andrea and Zanusso, Gianluigi and Antelmi, Elena and Okuzumi, Ayami and Zatti, Cinzia and Lupini, Alessandro and Bongianni, Matilde and Padovani, Alessandro and Hattori, Nobutaka},
title = {Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson’s Disease},
journal = {Journal of Parkinson’s Disease},
year = {2024},
doi = {10.3233/jpd-240007}
}
EUVIMED